Helping Pharmaceutical Companies Navigate Global Risk and Opportunity
Pharmaceutical companies are facing both challenging and promising times changing business models, emerging markets, new technologies, changing stakeholder expectations, increasing healthcare expenditure, shifting demographics and aging populations. Ernst & Young’s Global Pharmaceutical Center brings together a worldwide team of professionals to help you achieve your potential - a team with deep technical experience in providing assurance, tax, transaction and advisory services. The Center works to anticipate market trends, identify the implications and develop points of view on relevant industry issues. Ultimately it enables us to help you meet your goals and compete more effectively. It’s how Ernst & Young makes a difference. Visit our Global Pharmaceuticals site to learn about the Center and for industry insights that cover the global market. Pharmaceutical industry needs to speed up transformation to meet changing market dynamics according to Ernst & Young report Leaders of the largest global pharmaceutical companies recognize the need for transformational change in their organizations, but will need to move swiftly to ensure sustained growth for the sector. Current global financial conditions and the threat of a broad recession have accelerated the timetable for implementing change, as the industry confronts lower corporate stock prices and an increasingly cost-averse customer. These and other findings were released today in Progressions, Executing for success: powering new business models, Ernst & Young’s bi-annual global pharmaceutical report.
Read more... | Lessons from change: the life sciences industry How can you manage your company through the recession and position yourself for growth? After interviewing thousands of life sciences executives, we identified some overarching themes. From managing risks to improving capital allocation, we reveal the lessons that could mean the difference between surviving and thriving in the new economic environment. Prescriptions: optimizing supply chain management As the pharmaceutical industry undertakes a major overhaul of the traditional business model, supply chain optimization and operations effectiveness to “right-size” the business have become an important part of that change. Particularly relevant in this economic climate, we examine a number of challenges in supply chain management (Pdf, 104kb) from a variety of perspectives including tax effectiveness, regulatory compliance, cost improvement, risk management, product distribution and safety. Pharmaceutical industry needs to speed up transformation to meet changing market dynamics Leaders of the largest global pharmaceutical companies recognize the need for transformational change in their organizations, but will need to move swiftly to ensure sustained growth for the sector. Current global financial conditions and the threat of a broad recession have accelerated the timetable for implementing change, as the industry confronts lower corporate stock prices and an increasingly cost-averse customer. These and other findings were released in Progressions, Executing for success: powering new business models, Ernst & Young’s bi-annual global pharmaceutical report. Life sciences insights: changing times In this issue of our quarterly, Life sciences insights (Pdf, 384kb), we explore the current dynamics of the global financial crisis and its impact on the life sciences industry, the emergence of risk evaluation mitigation strategies (REMSs) mandated by the Food and Drug Administration and the deregulation of pharmacies and over-the-counter medications in Europe. Read our perspective on these topics and their impact on our ever-changing industry. Insights into the pharmaceutical industry in emerging markets As the financial crisis continues its impact on the global marketplace, what are the challenges and opportunities facing pharmaceuticals industry in emerging markets? (Pdf, 400kb). This engaging topic was discussed during Ernst & Young’s Global Pharmaceutical Center’s recent launch of our annual report, Progressions, in Brazil, Mexico, Japan and China. Read insights from our discussions with pharma industry leaders in each country. |
| |
